KOL Webinar on Neuroinflammation and Insulin Resistance and New Treatment Approaches for
Alzheimer's Disease (AD)
Hosted by BioVie, Inc. (NASDAQ: BIVI)
|
|
The webinar will feature presentations by Key Opinion Leaders (KOLs) Jefferson Kinney, Ph.D. (University of Nevada, Las Vegas) who will discuss the basis of inflammation as a central mechanism in Alzheimer’s disease, and Karl Herrup, Ph.D. (University of Pittsburgh School of Medicine) who will discuss the importance of age-related hyperinsulinemia and brain insulin resistance in neurodegeneration.
BioVie's management team will also discuss NE3107 for the treatment of Alzheimer's disease. NE3107’s mechanism acts on both the fundamental inflammatory signaling pathways and the consequent insulin resistance that are the root causes of Alzheimer’s and other neurodegenerative diseases. BioVie recently announced that the Company has enrolled the first patient into the NM101 Phase III clinical study testing NE3107 for the treatment of Alzheimer’s Disease (AD). The NM101 study is a potentially pivotal Phase 3, randomized, double-blind, placebo-controlled, US multicenter study of NE3107 in 316 subjects with mild to moderate AD.
A live Q&A session will follow the formal presentations.
|
|
You are required to register in advance for this webcast. For those who are unable to listen at this time, a replay of the event will be available by clicking here.
|
|
Q&A Information
If you would like to ask a question during the live Q&A, please submit your request via email.
|
|
Jefferson Kinney, Ph.D.
Jefferson Kinney, Ph.D., is the Founding Chair of the Department of Brain Health and holds the Reg Grundy and Joy Chambers-Grundy Chair for Brain Health in the Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV). He is the Director of the Cellular and Molecular Brain Research Laboratory and the Translational Biomarker Discovery Laboratory. Dr. Kinney earned his Ph.D. at Colorado State University and was awarded an Intramural Research Training Fellowship at the National Institute of Mental Health investigating the biology and behavior of transgenic mouse models of Alzheimer’s disease. He was then selected as the Helen Dorris Fellow in the Department of Neuropharmacology at The Scripps Research Institute where he conducted research on molecular mechanisms in neurological disorders. He joined the UNLV faculty in 2007. Dr. Kinney’s primary research focus is on investigating cellular and molecular mechanisms underlying Alzheimer’s decease with particular emphasis on neuronal-glial interactions. Dr. Kinney’s work is directed at understanding how specific immune signaling pathways are altered in pre-clinical Alzheimer laboratory models, as well as understanding the mechanisms underlying how Diabetes confers increased risk for developing Alzheimer’s disease. More recently, Dr. Kinney has expanded these investigations into biomarker discovery research projects in clinical populations. Dr. Kinney’s translational research approach is aimed at identifying disease mechanisms that may serve as new therapeutic targets as well as discovering novel biomarkers that can be used in detection, diagnosis, and evaluation of treatment efficacy of Alzheimer’s disease. Dr. Kinney’s research provides a foundation for understanding the risk of developing AD and the utility of personalized treatment approaches to preserve brain health. Dr. Kinney received the Top Tier Scientist Award, among the most prestigious honors bestowed by UNLV.
|
|
Karl Herrup, Ph.D.
Karl Herrup, Ph.D., received his Bachelor’s degree from Brandeis University in Waltham, MA and his Ph.D. in Neuroscience from Stanford University. After two postdoctoral fellowships – in Neurogenetics at Children’s Hospital/Harvard Medical School, and in Neuropharmacology at the Biozentrum in Basel Switzerland – he joined the faculty of the Human Genetics Department of Yale Medical School as an Assistant, then Associate, Professor. He became Director of the Division of Developmental Neurobiology at the E. K. Shriver Center in Waltham, MA before moving to the Departments of Neurosciences and Neurology at Case Western Reserve University Medical School and University Hospitals of Cleveland. While in Cleveland, he directed the University Alzheimer’s Center for six years. In 2006 he moved to the Piscataway/New Brunswick campus of Rutgers University to become Professor and Chair of the Department of Cell Biology and Neuroscience. In July 2012, he moved to Hong Kong to become the Head of Life Science at The Hong Kong University of Science and Technology. He returned to the United States in March 2019 to become a Professor of Neurobiology at the University of Pittsburgh. His laboratory research is focused on the biology of nerve cell death and the paradoxical role that failed cell cycle regulation plays in the process. His work includes a strong translational interest that directs his studies towards a few select human neurodegenerative diseases including Alzheimer’s, a very common late-life dementia, and ataxia-telangiectasia, a very rare multisystem disorder of childhood.
|
|
|
|
250 West 55th Street, Suite 3401
New York, NY 10019
|
|
Copyright © 2021 LifeSci Advisors, LLC, All rights reserved.
This message contains confidential and proprietary information and is intended only for the individual named. If you are not the named addressee you should not disseminate, distribute or copy this e-mail. Please notify the sender immediately by e-mail if you have received this email by mistake and delete this email from your system. All market prices, data and other information contained in this email are not warranted as to completeness or accuracy and are subject to change without notice. Any comments or statements made herein do not necessarily reflect the views of LifeSci Advisors, LLC, its affiliates, subsidiaries or agents. The message is not intended as an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Before opening any attachments please check them for viruses and defects.
|
|
|
|
|
|
|
